{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:07:09Z","timestamp":1793862429095,"version":"4.6.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/objective<\/jats:title>\n                <jats:p>Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic collagen disorder characterized by skin fragility leading to blistering, wounds, and scarring. There are currently no approved curative therapies. The objective of this manuscript is to provide a comprehensive literature review of the disease burden caused by RDEB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic literature review was conducted in MEDLINE and Embase in accordance with PRISMA guidelines. Observational and interventional studies on the economic, clinical, or humanistic burden of RDEB were included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixty-five studies were included in the review. Patients had considerable wound burden, with 60% reporting wounds covering more than 30% of their body. Increases in pain and itch were seen with larger wound size. Chronic wounds were larger and more painful than recurrent wounds. Commonly reported symptoms and complications included lesions and blistering, anemia, nail dystrophy and loss, milia, infections, musculoskeletal contractures, strictures or stenoses, constipation, malnutrition\/nutritional problems, pseudosyndactyly, ocular manifestations, and dental caries. Many patients underwent esophageal dilation (29\u201374%; median dilations, 2\u20136) and gastrostomy tube placement (8\u201358%). In the severely affected population, risk of squamous cell carcinoma (SCC) was 76% and mortality from SCC reached 84% by age 40. Patients with RDEB experienced worsened quality of life (QOL), decreased functioning and social activities, and increased pain and itch when compared to other EB subtypes, other skin diseases, and the general population. Families of patients reported experiencing high rates of burden including financial burden (50\u201354%) and negative impact on private life (79%). Direct medical costs were high, though reported in few studies; annual payer-borne total medical costs in Ireland were $84,534 and annual patient-borne medical costs in Korea were $7392. Estimated annual US costs for wound dressings ranged from $4000 to $245,000. Patients spent considerable time changing dressings: often daily (13\u201354% of patients) with up to three hours per change (15\u201340%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with RDEB and their families\/caregivers experience significant economic, humanistic, and clinical burden. Further research is needed to better understand the costs of disease, how the burden of disease changes over the patient lifetime and to better characterize QOL impact, and how RDEB compares with other chronic, debilitating disorders.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01811-7","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T13:14:14Z","timestamp":1618319654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa"],"prefix":"10.1186","volume":"16","author":[{"given":"Jean Yuh","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Peter","family":"Marinkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Gorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Gillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipen","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2298-2012","authenticated-orcid":false,"given":"Dan","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"issue":"5","key":"1811_CR1","first-page":"41","volume":"8","author":"L Soro","year":"2015","unstructured":"Soro L, Bartus C, Purcell S. Recessive dystrophic epidermolysis bullosa: a review of disease pathogenesis and update on future therapies. J Clin Aesthet Dermatol. 2015;8(5):41\u20136.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"11","key":"1811_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","volume":"152","author":"J-D Fine","year":"2016","unstructured":"Fine J-D. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the National Epidermolysis Bullosa Registry. JAMA Dermatol. 2016;152(11):1231\u20138.","journal-title":"JAMA Dermatol"},{"key":"1811_CR3","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2147\/CCID.S232547","volume":"12","author":"S Eichstadt","year":"2019","unstructured":"Eichstadt S, Tang JY, Solis DC, Siprashvili Z, Marinkovich MP, Whitehead N, et al. From clinical phenotype to genotypic modelling: incidence and prevalence of recessive dystrophic epidermolysis bullosa (RDEB). Clin Cosmet Investig Dermatol. 2019;12:933\u201342.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"1811_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","volume":"70","author":"J-D Fine","year":"2014","unstructured":"Fine J-D, Bruckner-Tuderman L, Eady RAJ, Bauer EA, Bauer JW, Has C, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103\u201326.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1811_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614\u201327.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1811_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2340\/00015555-2781","volume":"98","author":"M Kim","year":"2018","unstructured":"Kim M, Li M, Intong-Wheeler LRA, Tran K, Marucci D, Murrell DF. Epidemiology and outcome of squamous cell carcinoma in epidermolysis bullosa in Australia and New Zealand. Acta Derm Venereol. 2018;98(1):70\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1811_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5582\/irdr.2017.01005","volume":"6","author":"E Rashidghamat","year":"2017","unstructured":"Rashidghamat E, McGrath JA. Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa. Intract Rare Dis Res. 2017;6(1):6\u201320.","journal-title":"Intract Rare Dis Res"},{"key":"1811_CR8","unstructured":"Denyer J, Pillay E, Clapman J. Best practice guidelines for skin and wound care in epidermolysis bullosa. London, UK: Dystrophic Epidermolysis Bullosa Research Association; 2017 [cited 2021 January 15]. https:\/\/www.woundsinternational.com\/resources\/details\/best-practice-guidelines-skin-and-wound-care-in-epidermolysis-bullosa."},{"key":"1811_CR9","unstructured":"Liy-Wong C, Ali A, Aujla N, Briggs L, Campbell F, El Hamouly A, et al. Epidermolysis bullosa, a handbook for EB patients and families. Toronto, ON: DEBRA Canada; [cited 2021 January 15]. https:\/\/www.sickkids.ca\/Dermatology\/What-we-do\/76382-EBook_Final_Interactive.pdf."},{"key":"1811_CR10","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Epidermolysis bullosa: developing drugs for treatment of cutaneous manifestations, guidance for industry. Silver Spring, MD: Food and Drug Administration; 2019 [cited 2021 January 15]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/epidermolysis-bullosa-developing-drugs-treatment-cutaneous-manifestations-guidance-industry."},{"issue":"5","key":"1811_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/13543776.2019.1608181","volume":"29","author":"M Dourado Alcorte","year":"2019","unstructured":"Dourado Alcorte M, Sogayar MC, Demasi MA. Patent landscape of molecular and cellular targeted therapies for recessive dystrophic epidermolysis bullosa. Expert Opin Ther Pat. 2019;29(5):327\u201337.","journal-title":"Expert Opin Ther Pat"},{"issue":"19","key":"1811_CR12","doi-asserted-by":"publisher","first-page":"e130554","DOI":"10.1172\/jci.insight.130554","volume":"4","author":"S Eichstadt","year":"2019","unstructured":"Eichstadt S, Barriga M, Ponakala A, Teng C, Nguyen NT, Siprashvili Z, et al. Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa. JCI Insight. 2019;4(19):e130554.","journal-title":"JCI Insight"},{"issue":"6","key":"1811_CR13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jid.2018.11.036","volume":"139","author":"MP Marinkovich","year":"2019","unstructured":"Marinkovich MP, Tang JY. Gene therapy for epidermolysis bullosa. J Investig Dermatol. 2019;139(6):1221\u20136.","journal-title":"J Investig Dermatol"},{"issue":"17","key":"1811_CR14","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1001\/jama.2016.15588","volume":"316","author":"Z Siprashvili","year":"2016","unstructured":"Siprashvili Z, Nguyen NT, Gorell ES, Loutit K, Khuu P, Furukawa LK, et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA. 2016;316(17):1808\u201317.","journal-title":"JAMA"},{"issue":"7","key":"1811_CR15","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"8","key":"1811_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-4362.1993.tb05029.x","volume":"32","author":"AA Abahussein","year":"1993","unstructured":"Abahussein AA, Al-Zayir AA, Mostafa WZ, Okoro AN. Epidermolysis bullosa in the Eastern Province of Saudi Arabia. Int J Dermatol. 1993;32(8):579\u201381.","journal-title":"Int J Dermatol"},{"key":"1811_CR17","unstructured":"Alband N, Kumar DS, Jones R, James D, Ogboli M, Browne F, et al. Morbidity and mortality in U.K. children with recessive dystrophic epidermolysis bullosa: 16-year data from the National UK. EB Registry. British Journal of Dermatology. 2016;175:161."},{"key":"1811_CR18","first-page":"179","volume":"86","author":"LC Castro","year":"2016","unstructured":"Castro LC, Nobrega Y, Gandolfi L, Pratesi R. Bone mass and Vitamin D status in children and adolescents with generalized epidermolysis bullosa. Hormone Res Paediat. 2016;86:179.","journal-title":"Hormone Res Paediat"},{"issue":"3","key":"1811_CR19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/jdv.15337","volume":"33","author":"PV Chernyshov","year":"2019","unstructured":"Chernyshov PV, Suru A, Gedeon I, Derevyanko LA, Tiplica GS, Salavastru CM. Epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life (InToDermQoL) questionnaire. J Eur Acad Dermatol Venereol. 2019;33(3):612\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1811_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1365-2133.2011.10592.x","volume":"166","author":"V Colomb","year":"2012","unstructured":"Colomb V, Bourdon-Lannoy E, Lambe C, Sauvat F, Hadj Rabia S, Teillac D, et al. Nutritional outcome in children with severe generalized recessive dystrophic epidermolysis bullosa: a short- and long-term evaluation of gastrostomy and enteral feeding. Br J Dermatol. 2012;166(2):354\u201361.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1811_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.2298\/VSP151023159C","volume":"74","author":"A \u010colovi\u0107","year":"2017","unstructured":"\u010colovi\u0107 A, Jovi\u010di\u0107 O, Stevanovi\u0107 R, Ivanovi\u0107 M. Oral health status in children with inherited dystrophic epidermolysis bullosa. Vojnosanit Pregl. 2017;74(7):644\u201351.","journal-title":"Vojnosanit Pregl"},{"issue":"5","key":"1811_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1808-8694(15)31373-2","volume":"74","author":"RS Fantauzzi","year":"2008","unstructured":"Fantauzzi RS, Maia MO, Cunha FC, Sim\u00f5es RV, Gon\u00e7alves DU, Maia AF. Otorhinolaryngological and esophageal manifestations of epidermolysis bullosa. Braz J Otorhinolaryngol. 2008;74(5):657\u201361.","journal-title":"Braz J Otorhinolaryngol"},{"issue":"2","key":"1811_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/jamadermatol.2018.4673","volume":"155","author":"JA Feinstein","year":"2018","unstructured":"Feinstein JA, Jambal P, Peoples K, Lucky AW, Khuu P, Tang JY, et al. Assessment of the timing of milestone clinical events in patients with epidermolysis bullosa from North America. JAMA Dermatol. 2018;155(2):196\u2013203.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1811_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-0031-1295437","volume":"224","author":"R Feldmann","year":"2012","unstructured":"Feldmann R, Weglage J, Frosch M. Cognitive function in patients with epidermolysis bullosa: social adjustment and emotional problems. Klin Padiatr. 2012;224(1):22\u20135.","journal-title":"Klin Padiatr"},{"issue":"3","key":"1811_CR25","first-page":"677","volume":"159","author":"JD Fine","year":"2008","unstructured":"Fine JD, Hall M, Weiner M, Li KP, Suchindran C. The risk of cardiomyopathy in inherited epidermolysis bullosa. Br J Dermatol. 2008;159(3):677\u201382.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1811_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","volume":"60","author":"J-D Fine","year":"2009","unstructured":"Fine J-D, Johnson LB, Weiner M, Li K-P, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986\u20132006. J Am Acad Dermatol. 2009;60(2):203\u201311.","journal-title":"J Am Acad Dermatol"},{"key":"1811_CR27","doi-asserted-by":"crossref","unstructured":"Fine J-D, Johnson LB, Weiner M, Stein A, Cash S, DeLeoz J, et al. Genitourinary complications of inherited epidermolysis bullosa: experience of the national epidermylosis bullosa registry and review of the literature. J Urol. 2004;172(5 I):2040\u20134.","DOI":"10.1097\/01.ju.0000143200.86683.2c"},{"issue":"1","key":"1811_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/J.JHSB.2004.07.006","volume":"30","author":"J-D Fine","year":"2005","unstructured":"Fine J-D, Johnson LB, Weiner M, Stein A, Cash S, DeLeoz J, et al. Pseudosyndactyly and musculoskeletal contractures in inherited epidermolysis bullosa: experience of the national epidermolysis bullosa registry, 1986\u20132002. J Hand Surg. 2005;30(1):14\u201322.","journal-title":"J Hand Surg"},{"issue":"9","key":"1811_CR29","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1097\/MLG.0b013e318093ed8e","volume":"117","author":"J-D Fine","year":"2007","unstructured":"Fine J-D, Johnson LB, Weiner M, Suchindran C. Tracheolaryngeal complications of inherited epidermolysis bullosa: cumulative experience of the national epidermolysis bullosa registry. Laryngoscope. 2007;117(9):1652\u201360.","journal-title":"Laryngoscope"},{"issue":"2","key":"1811_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/MPG.0b013e31812f5667","volume":"46","author":"J-D Fine","year":"2008","unstructured":"Fine J-D, Johnson LB, Weiner M, Suchindran C. Gastrointestinal complications of inherited epidermolysis bullosa: cumulative experience of the national epidermolysis bullosa registry. J Pediatr Gastroenterol Nutr. 2008;46(2):147\u201358.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"1811_CR31","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1365-2133.2008.08507.x","volume":"158","author":"EB Freeman","year":"2008","unstructured":"Freeman EB, K\u00f6glmeier J, Martinez AE, Mellerio JE, Haynes L, Sebire NJ, et al. Gastrointestinal complications of epidermolysis bullosa in children. Br J Dermatol. 2008;158(6):1308\u201314.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1811_CR32","doi-asserted-by":"publisher","first-page":"778","DOI":"10.2214\/AJR.16.16115","volume":"207","author":"JD Guerra-Leal","year":"2016","unstructured":"Guerra-Leal JD, Meester I, Cantu-Gonzalez JR, Ornelas-Cortinas G, Montemayor-Martinez A, Salas-Alanis JC. The importance of esophagography in patients with recessive dystrophic epidermolysis bullosa. Am J Roentgenol. 2016;207(4):778\u201381.","journal-title":"Am J Roentgenol"},{"issue":"2","key":"1811_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1046\/j.1365-2133.2002.04607.x","volume":"146","author":"HM Horn","year":"2002","unstructured":"Horn HM, Tidman MJ. The clinical spectrum of dystrophic epidermolysis bullosa. Br J Dermatol. 2002;146(2):267\u201374.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1811_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijwd.2014.12.001","volume":"1","author":"SJE Hwang","year":"2015","unstructured":"Hwang SJE, Daniel BS, Fergie B, Davey J, Murrell DF. Prevalence of anemia in patients with epidermolysis bullosa registered in Australia. Int J Women\u2019s Dermatol. 2015;1(1):37\u201340.","journal-title":"Int J Women's Dermatol"},{"issue":"1","key":"1811_CR35","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ijwd.2017.02.002","volume":"3","author":"LRA Intong","year":"2017","unstructured":"Intong LRA, Choi SD, Shipman A, Kho YC, Hwang SJE, Rhodes LM, et al. Retrospective evidence on outcomes and experiences of pregnancy and childbirth in epidermolysis bullosa in Australia and New Zealand. Int J Women\u2019s Dermatol. 2017;3(1):S1\u20135.","journal-title":"Int J Women's Dermatol"},{"issue":"10","key":"1811_CR36","doi-asserted-by":"publisher","first-page":"E589","DOI":"10.1016\/S0735-1097(13)60589-6","volume":"61","author":"JL Jefferies","year":"2013","unstructured":"Jefferies JL, Towbin J, Ryan T, Lucky A. Cardiovascular findings in recessive dystrophic epidermolysis bullosa. J Am Coll Cardiol. 2013;61(10):E589.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1811_CR37","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.ophtha.2015.12.040","volume":"123","author":"SM Jones","year":"2016","unstructured":"Jones SM, Smith KA, Jain M, Mellerio JE, Martinez A, Nischal KK. The frequency of signs of meibomian gland dysfunction in children with epidermolysis bullosa. Ophthalmology. 2016;123(5):991\u20139.","journal-title":"Ophthalmology"},{"issue":"3","key":"1811_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000018384","volume":"200","author":"K Kaneko","year":"2000","unstructured":"Kaneko K, Kakuta M, Ohtomo Y, Shimizu T, Yamashiro Y, Ogawa H, et al. Renal amyloidosis in recessive dystrophic epidermolysis bullosa. Dermatology. 2000;200(3):209\u201312.","journal-title":"Dermatology"},{"issue":"3","key":"1811_CR39","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1525-1470.2010.01127.x","volume":"27","author":"I Lara-Corrales","year":"2010","unstructured":"Lara-Corrales I, Mellerio JE, Martinez AE, Green A, Lucky AW, Azizkhan RG, et al. Dilated cardiomyopathy in epidermolysis bullosa: a retrospective, multicenter study. Pediatr Dermatol. 2010;27(3):238\u201343.","journal-title":"Pediatr Dermatol"},{"key":"1811_CR40","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s10388-016-0538-4","volume":"13","author":"P Markos","year":"2016","unstructured":"Markos P, Karaman M, Murat-Susic S, Omerza L, Pulanic R, Rustemovic N. Dilatation of esophageal strictures in epidermolysis bullosa patients: a single center experience. Esophagus. 2016;13:378\u201382.","journal-title":"Esophagus"},{"key":"1811_CR41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/bjd.16985","volume":"179","author":"C McDonald","year":"2018","unstructured":"McDonald C, Roebuck D, Mellerio J, Martinez A. Can we predict the chronology of oesophageal strictures in paediatric epidermolysis bullosa patients? A prospective study of 75 children. Br J Dermatol. 2018;179:165\u20136.","journal-title":"Br J Dermatol"},{"key":"1811_CR42","doi-asserted-by":"crossref","unstructured":"Mellado F, Fuentes I, Palisson F, I Vergara J, Kantor A. Ophthalmologic approach in epidermolysis bullosa: a cross-sectional study with phenotype\u2013genotype correlations. Cornea. 2018;37(4):442\u20137.","DOI":"10.1097\/ICO.0000000000001525"},{"issue":"5","key":"1811_CR43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1346-8138.1993.tb01390.x","volume":"20","author":"K Nomura","year":"1993","unstructured":"Nomura K, Imaizumi T, Sato T, Hashimoto I. Clinical criteria for differentiating between recessive and dominant forms of dystrophic epidermolysis bullosa, elaborated from an analysis of 119 cases. J Dermatol. 1993;20(5):269\u201375.","journal-title":"J Dermatol"},{"key":"1811_CR44","doi-asserted-by":"crossref","unstructured":"Rao A, Mellerio JE, Sklar M, Brain C, Allgrove J, Sanderson IR, et al. Growth impaired children with epidermolysis bullosa have increased serum markers of inflammation and reduced circulating IGF-I\/IGFBP-3. Pediatr Res. 2011;70:294.","DOI":"10.1038\/pr.2011.519"},{"issue":"3","key":"1811_CR45","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/bjd.14168","volume":"174","author":"TD Ryan","year":"2016","unstructured":"Ryan TD, Lucky AW, King EC, Huang G, Towbin JA, Jefferies JL. Ventricular dysfunction and aortic dilation in patients with recessive dystrophic epidermolysis bullosa. Br J Dermatol. 2016;174(3):671\u20133.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1811_CR46","doi-asserted-by":"publisher","first-page":"A944","DOI":"10.1016\/S0735-1097(15)60944-5","volume":"65","author":"TD Ryan","year":"2015","unstructured":"Ryan TD, Lucky AW, Towbin J, Jefferies J. Ventricular dysfunction and aortic dilation in patients with recessive dystrophic epidermolysis bullosa. J Am Coll Cardiol. 2015;65(10):A944.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1811_CR47","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/j.1468-3083.2012.04682.x","volume":"27","author":"F Sampogna","year":"2013","unstructured":"Sampogna F, Tabolli S, Di Pietro C, Castiglia D, Zambruno G, Abeni D. The evaluation of family impact of recessive dystrophic epidermolysis bullosa using the Italian version of the family dermatology life quality index. J Eur Acad Dermatol Venereol. 2013;27(9):1151\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1811_CR48","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1034\/j.1601-0825.2003.03971.x","volume":"9","author":"MC Serrano-Mart\u00ednez","year":"2003","unstructured":"Serrano-Mart\u00ednez MC, Bag\u00e1n JV, Silvestre FJ, Viguer MT. Oral lesions in recessive dystrophic epidermolysis bullosa. Oral Dis. 2003;9(5):264\u20138.","journal-title":"Oral Dis"},{"issue":"1","key":"1811_CR49","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/adc.83.1.59","volume":"83","author":"RU Sidwell","year":"2000","unstructured":"Sidwell RU, Yates R, Atherton D. Dilated cardiomyopathy in dystrophic epidermolysis bullosa. Arch Dis Child. 2000;83(1):59\u201363.","journal-title":"Arch Dis Child"},{"issue":"3","key":"1811_CR50","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1684\/ejd.2011.1356","volume":"21","author":"C Stellingsma","year":"2011","unstructured":"Stellingsma C, Dijkstra PU, Dijkstra J, Duipmans JC, Jonkman MF, Dekker R. Restrictions in oral functions caused by oral manifestations of epidermolysis bullosa. Eur J Dermatol. 2011;21(3):405\u20139.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"1811_CR51","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/bjo.83.3.323","volume":"83","author":"L Tong","year":"1999","unstructured":"Tong L, Hodgkins PR, Denyer J, Brosnahan D, Harper J, Russell-Eggitt I, et al. The eye in epidermolysis bullosa. Br J Ophthalmol. 1999;83(3):323\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"1811_CR52","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa0910501","volume":"363","author":"JE Wagner","year":"2010","unstructured":"Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Riddle MJ, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med. 2010;363(7):629\u201339.","journal-title":"N Engl J Med"},{"issue":"1","key":"1811_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","volume":"15","author":"AL Bruckner","year":"2020","unstructured":"Bruckner AL, Losow M, Wisk J, Patel N, Reha A, Lagast H, et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020;15(1):1.","journal-title":"Orphanet J Rare Dis"},{"key":"1811_CR54","doi-asserted-by":"publisher","unstructured":"Eng VA, Solis DC, Gorell ES, Choi S, Nazaroff J, Li S, et al. Patient reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: a global cross-sectional survey. J Am Acad Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.028. Online ahead of print.","DOI":"10.1016\/j.jaad.2020.03.028"},{"key":"1811_CR55","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/bjd.18475","volume":"182","author":"A Reimer","year":"2019","unstructured":"Reimer A, Hess M, Schwieger-Briel A, Kiritsi D, Schauer F, Schumann H, et al. Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study. Br J Dermatol. 2019;182:1437\u201348.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1811_CR56","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jid.2019.03.327","volume":"139","author":"C Teng","year":"2019","unstructured":"Teng C, Solis D, Tang J, Barriga M, Marinkovich MP. 251 Natural history of wounds in patients with recessive dystrophic epidermolysis bullosa. J Investig Dermatol. 2019;139(5):S43.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1811_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/pde.12391","volume":"32","author":"C Danial","year":"2015","unstructured":"Danial C, Adeduntan R, Gorell ES, Lucky AW, Paller AS, Bruckner A, et al. Prevalence and characterization of pruritus in epidermolysis bullosa. Pediatr Dermatol. 2015;32(1):53\u20139.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"1811_CR58","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/j.1365-2230.2004.01428.x","volume":"29","author":"JD Fine","year":"2004","unstructured":"Fine JD, Johnson LB, Weiner M, Suchindran C. Assessment of mobility, activities and pain in different subtypes of epidermolysis bullosa. Clin Exp Dermatol. 2004;29(2):122\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1811_CR59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5021\/ad.2016.28.1.6","volume":"28","author":"IK Jeon","year":"2016","unstructured":"Jeon IK, On HR, Kim S-C. Quality of life and economic burden in recessive dystrophic epidermolysis bullosa. Ann Dermatol. 2016;28(1):6\u201314.","journal-title":"Ann Dermatol"},{"issue":"3","key":"1811_CR60","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2340\/00015555-2827","volume":"98","author":"NHB Schr\u00e4der","year":"2018","unstructured":"Schr\u00e4der NHB, Yuen WY, Jonkman MF. Pain quality assessment scale for epidermolysis bullosa. Acta Derm Venereol. 2018;98(3):346\u20139.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1811_CR61","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jid.2017.02.239","volume":"137","author":"S Choi","year":"2017","unstructured":"Choi S, Solis D, Nazaroff J, Bailey-Healy I, Barriga M, Dutt-Singkh Y, et al. Quality of life in recessive dystrophic epidermolysis bullosa: the AltaVoice patient registry, 2012\u20132015. J Investig Dermatol. 2017;137(5):S38.","journal-title":"J Investig Dermatol"},{"key":"1811_CR62","unstructured":"Mellerio J. PEBLES: natural history of RDEB. DEBRA International Congress; Zagreb, Croatia2016. p. 1-48."},{"issue":"2","key":"1811_CR63","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jpeds.2007.06.039","volume":"152","author":"J-D Fine","year":"2008","unstructured":"Fine J-D, Johnson LB, Weiner M, Suchindran C. Cause-specific risks of childhood death in inherited epidermolysis bullosa. J Pediatr. 2008;152(2):276-80.e2.","journal-title":"J Pediatr"},{"key":"1811_CR64","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s12094-019-02073-3","volume":"21","author":"B Castelo","year":"2019","unstructured":"Castelo B, Vi\u00f1al D, Maseda R, Ostios L, S\u00e1nchez D, Garc\u00eda-Salvatierra B, et al. Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years\u2019 experience of a reference centre in Spain. Clin Transl Oncol. 2019;21:1573\u20137.","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"1811_CR65","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1525-1470.2011.01612.x","volume":"29","author":"L Haynes","year":"2012","unstructured":"Haynes L, Mellerio JE, Martinez AE. Gastrostomy tube feeding in children with epidermolysis bullosa: Consideration of key issues. Pediatr Dermatol. 2012;29(3):277\u201384.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"1811_CR66","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jclinane.2005.11.004","volume":"18","author":"Y-C Lin","year":"2006","unstructured":"Lin Y-C, Golianu B. Anesthesia and pain management for pediatric patients with dystrophic epidermolysis bullosa. J Clin Anesth. 2006;18(4):268\u201371.","journal-title":"J Clin Anesth"},{"key":"1811_CR67","doi-asserted-by":"crossref","unstructured":"Andreoli E, Mozzetta A, Angelo C, Paradisi M, Foglio Bonda PG. Epidermolysis bullosa. Psychological and psychosocial aspects. Dermatol Psychosomat. 2002;3(2):77\u201381.","DOI":"10.1159\/000064496"},{"issue":"5","key":"1811_CR68","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/bjd.16350","volume":"178","author":"AL Bruckner","year":"2018","unstructured":"Bruckner AL, Fairclough DL, Feinstein JA, Lara-Corrales I, Lucky AW, Tolar J, et al. Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB). Br J Dermatol. 2018;178(5):1128\u201334.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1811_CR69","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1111\/ijd.12819","volume":"55","author":"T Cestari","year":"2016","unstructured":"Cestari T, Prati C, Menegon DB, Prado Oliveira ZN, Machado MCR, Dumet J, et al. Translation, cross-cultural adaptation and validation of the quality of life evaluation in Epidermolysis Bullosa instrument in Brazilian Portuguese. Int J Dermatol. 2016;55(2):e94\u20139.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1811_CR70","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/pde.12262","volume":"31","author":"EA Eismann","year":"2014","unstructured":"Eismann EA, Lucky AW, Cornwall R. Hand function and quality of life in children with epidermolysis bullosa. Pediatr Dermatol. 2014;31(2):176\u201382.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"1811_CR71","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1365-2133.2009.09347.x","volume":"161","author":"JW Frew","year":"2009","unstructured":"Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument. Br J Dermatol. 2009;161(6):1323\u201330.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1811_CR72","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/pde.12317","volume":"32","author":"A Schwieger-Briel","year":"2015","unstructured":"Schwieger-Briel A, Chakkittakandiyil A, Lara-Corrales I, Aujla N, Lane AT, Lucky AW, et al. Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool. Pediatr Dermatol. 2015;32(1):41\u201352.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"1811_CR73","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/bjd.18592","volume":"182","author":"K Soon","year":"2020","unstructured":"Soon K, Mason R, Martinez AE, Mellerio JE. The psychological functioning of children with epidermolysis bullosa and its relationship with specific aspects of disease. Br J Dermatol. 2020;182(3):789\u201390.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1811_CR74","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/j.1365-2133.2009.09041.x","volume":"160","author":"C Moss","year":"2009","unstructured":"Moss C, Wong A, Davies P. The Birmingham Epidermolysis Bullosa Severity score: development and validation. Br J Dermatol. 2009;160(5):1057\u201365.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1811_CR75","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/j.1365-2133.2004.06339.x","volume":"152","author":"J-D Fine","year":"2005","unstructured":"Fine J-D, Johnson LB, Weiner M, Suchindran C. Impact of inherited epidermolysis bullosa on parental interpersonal relationships, marital status and family size. Br J Dermatol. 2005;152(5):1009\u201314.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1811_CR76","first-page":"23","volume":"9","author":"P Grocott","year":"2013","unstructured":"Grocott P, Graham T, Blackwell R, Currie C, Pillay E, Clapham J, et al. Individualising wound care research: the woundcare for epidermolysis bullosa project. Wounds UK. 2013;9(3):23\u201332.","journal-title":"Wounds UK"},{"issue":"1","key":"1811_CR77","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/pde.12243","volume":"31","author":"AY Kirkorian","year":"2014","unstructured":"Kirkorian AY, Weitz NA, Tlougan B, Morel KD. Evaluation of wound care options in patients with recessive dystrophic epidermolysis bullosa: a costly necessity. Pediatr Dermatol. 2014;31(1):33\u20137.","journal-title":"Pediatr Dermatol"},{"key":"1811_CR78","doi-asserted-by":"crossref","unstructured":"Flannery D, Doyle C, Hickey S, Aherne F, Kenan A. Direct costs of epidermolysis bullosa by disease severity. Acta Dermatovenereol. 2020;100(8):adv00116.","DOI":"10.2340\/00015555-3456"},{"issue":"2","key":"1811_CR79","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/pde.14102","volume":"37","author":"LH Shayegan","year":"2020","unstructured":"Shayegan LH, Levin LE, Galligan ER, Lucky AW, Bruckner AL, Pope E, et al. Skin cleansing and topical product use in patients with epidermolysis bullosa: results from a multicenter database. Pediatr Dermatol. 2020;37(2):326\u201332.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"1811_CR80","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/bjd.18128","volume":"182","author":"C Has","year":"2020","unstructured":"Has C, Liu L, Bolling MC, Charlesworth AV, El Hachem M, Esc\u00e1mez MJ, et al. Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa. Br J Dermatol. 2020;182(3):574\u201392.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1811_CR81","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ad.2017.08.008","volume":"109","author":"C S\u00e1nchez-Jimeno","year":"2018","unstructured":"S\u00e1nchez-Jimeno C, Esc\u00e1mez MJ, Ayuso C, Trujillo-Tiebas MJ, Del R\u00edo M. Genetic diagnosis of epidermolysis bullosa: recommendations from an expert Spanish research group. Actas Dermosifiliogr. 2018;109(2):104\u201322.","journal-title":"Actas Dermosifiliogr"},{"key":"1811_CR82","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bjd.13870","volume":"173","author":"J Mellerio","year":"2015","unstructured":"Mellerio J, Robertson S, Pillay E, Denyer J, Wedgeworth E, Batten E, et al. A systematic review of the natural history of recessive dystrophic epidermolysis bullosa. Br J Dermatol. 2015;173:42.","journal-title":"Br J Dermatol"},{"key":"1811_CR83","doi-asserted-by":"crossref","unstructured":"Montaudi\u00e9 H, Chiaverini C, Sbidian E, Charlesworth A, Lacour JP. Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases. Orphanet J Rare Dis. 2016;11:117.","DOI":"10.1186\/s13023-016-0489-9"},{"issue":"6","key":"1811_CR84","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/pde.14340","volume":"37","author":"ES Gorell","year":"2020","unstructured":"Gorell ES, Wolstencroft PW, de Souza MP, Murrell DF, Linos E, Tang JY. Financial burden of epidermolysis bullosa on patients in the United States. Pediatr Dermatol. 2020;37(6):1198\u2013201.","journal-title":"Pediatr Dermatol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01811-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01811-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01811-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T11:14:22Z","timestamp":1675163662000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01811-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,13]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1811"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01811-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,13]]},"assertion":[{"value":"3 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JYT and MPM are investigators for Abeona Therapeutics (VIITAL trial). YL serves in consulting\/advisory roles to Nektar Therapeutics and Gilead Sciences. JYT serves in a consulting role to BridgeBio Pharma and PellePharm. AC serves in a consulting\/advisory role to Pfizer and AbbVie.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}